Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
Daniel Ayoubkhani,Charlotte R Bermingham,Koen B. Pouwels,Myer Glickman,Vahé Nafilyan,Francesco Zaccardi,Kamlesh Khunti,Nisreen A Alwan,A. Walker +8 more
Reads0
Chats0
TLDR
The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days, although longer follow- up is needed.Abstract:
Abstract Objective To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. Design Observational cohort study. Setting Community dwelling population, UK. Participants 28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection. Main outcome measure Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021. Results Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval −18.6% to −6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval −0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval −14.1% to −3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (−1.2% to −0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination. Conclusions The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed.read more
Citations
More filters
Journal ArticleDOI
The Lancet Commission on lessons for the future from the COVID-19 pandemic
TL;DR: The COVID-19 Commission report as mentioned in this paper provides a conceptual framework for understanding pandemics and proposes guideposts for strengthening the multilateral system to address global emergencies and to achieve sustainable development.
Journal ArticleDOI
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review
Kin Israel Notarte,Jesus Alfonso Catahay,Jacqueline Veronica Velasco,Adriel M. Pastrana,Abbygail Therese Ver,Flos Carmeli Pangilinan,Princess Juneire Peligro,Michael Casimiro,Jonathan Jaime Guerrero,Ma. Margarita Leticia Gellaco,Giuseppe Lippi,Brandon Michael Henry,César Fernández-de-las-Peñas +12 more
TL;DR: In this paper , a systematic review was conducted to investigate the association between COVID-19 vaccination and long-COVID symptomatology, finding that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-coVID.
Journal ArticleDOI
The Lancet Commission on lessons for the future from the COVID-19 pandemic
Jeffrey D. Sachs,Salim S. Abdool Karim,Lara B. Aknin,J. Allen,Kirsten Brosbøl,Francesca Colombo,Gabriela Cuevas Barron,María Fernanda Espinosa,Vitor Gaspar,Alejandro Gaviria,Andy Haines,Peter J. Hotez,Phoebe Koundouri,Felipe Larraín Bascuñán,Jong Koo Lee,Muhammad Pate,Gabriela Ramos,K.S. Reddy,Ismail Serageldin,John Thwaites,Vaira Vike-Freiberga,Chen Wang,Miriam Were,Lan Xue,Chandrika Bahadur,Maria Elena Bottazzi,Chris Bullen,George Laryea-Adjei,Yanis Ben Amor,O. Karadag,Guillaume Lafortune,Emma Torres,Lauren Barredo,Juliana G E Bartels,Neena Joshi,Margaret Hellard,Uyen Kim Huynh,Shweta Khandelwal,Jeffrey V. Lazarus,Susan Michie +39 more
TL;DR: The winners will be announced at a special ceremony in New York later this month.
Journal ArticleDOI
Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study
Claire E. Hastie,David J Lowe,Andrew McAuley,Andrew Winter,Nicholas L. Mills,Corri Black,Janet T Scott,Catherine A. O’Donnell,David Blane,Susan Browne,Tracy R. Ibbotson,Jill P. Pell +11 more
TL;DR: A Scottish population cohort of 33,281 laboratory-confirmed SARS-CoV-2 infections and 62,957 never-infected individuals were followed-up via 6, 12 and 18-month questionnaires and linkage to hospitalization and death records as discussed by the authors .
Journal ArticleDOI
Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis
TL;DR: In this paper , the authors performed a meta-analysis to explore the relationship between vaccination and long COVID and found that the vaccination rate should be improved as soon as possible, especially for a complete vaccination course.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
TL;DR: Methods to determine the sampling distribution of the standardized difference when the true standardized difference is equal to zero are described, thereby allowing one to determined the range of standardized differences that are plausible with the propensity score model having been correctly specified.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
Interrupted time series regression for the evaluation of public health interventions: a tutorial
TL;DR: This tutorial uses a worked example to demonstrate a robust approach to ITS analysis using segmented regression and describes the main methodological issues associated with ITS analysis: over-dispersion of time series data, autocorrelation, adjusting for seasonal trends and controlling for time-varying confounders.
Journal ArticleDOI
Evolution of antibody immunity to SARS-CoV-2.
Christian Gaebler,Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Minami Tokuyama,Alice Cho,Mila Jankovic,Dennis Schaefer-Babajew,Thiago Y. Oliveira,Melissa Cipolla,Charlotte Viant,Christopher O. Barnes,Yaron Bram,Gaëlle Breton,Thomas Hagglof,Pilar Mendoza,Arlene Hurley,Martina Turroja,Kristie Gordon,Katrina G. Millard,Victor A. Ramos,Fabian Schmidt,Yiska Weisblum,Divya Jha,Michael Tankelevich,Gustavo Martinez-Delgado,Jim Yee,Roshni Patel,Juan Dizon,Cecille Unson-O'Brien,Irina Shimeliovich,Davide F. Robbiani,Zhen Zhao,Anna Gazumyan,Robert E. Schwartz,Theodora Hatziioannou,Pamela J. Bjorkman,Saurabh Mehandru,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +43 more
TL;DR: In this article, the authors report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection with SARS-CoV-2.
Related Papers (5)
Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus
A. Quattrocchi,Constantinos Tsioutis,Anna Demetriou,Theopisti Kyprianou,Maria Athanasiadou,Valentinos Silvestros,Ioannis Mamais,Christiana A. Demetriou,Fanitsa A. Theophanous,Soteroulla Soteriou,Chryso Gregoriadou,Eleni Anastasiou,Panayiotis Kolios,Christos Ηaralambous,Ioanna Gregoriou,O. Kalakouta,Georgios K. Nikolopoulos +16 more